P. Jeffrey Conn, Ph.D
DIRECTOR, VANDERBILT CENTER FOR NEUROSCIENCE DRUG DISCOVERY
Jeffrey Conn received the B.S. degree in Psychology and Biology from Lee Universiy in 1981 and the Ph.D. degree in Pharmacology from Vanderbilt University in 1986. He pursued postdoctoral studies in the Department of Pharmacology at Yale University. In 1988, Dr. Conn joined the faculty of the Department of Pharmacology at Emory University, where he rose to the rank of Full Professor and established himself as a leader in studies of neurotransmitter receptors and their roles in regulating brain function in circuits involved in psychiatric and neurological disorders. Dr. Conn moved to Merck and Company in 2000 to assume the position of Senior Director and Head of the Department of Neuroscience at Merck's site in West Point, PA.
In 2003, Dr. Conn moved to Vanderbilt University start a new Program in Drug Discovery, now the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics. In addition to being the Lee E. Limbird Professor of Pharmacology and Director of VCNDD, Dr. Conn is Editor in Chief of Molecular Pharmacology, Regional Editor (North America) of Current Neuropharmacology and serves on the editorial boards of 6 other international journals. Dr. Conn serves on the Scientific Advisory Boards of Addex Pharmaceuticals, Precient Neuropharma, Invitrogen Life Technologies, Seaside Therapeutics, Cephalon Inc., AstraZeneca US , Hoffman La Roche, Michael J. Fox Foundation, and the Dystonia Medical Research Foundation and Eyeforpharma Advisory Board on CNS Drugs. He is Chairman of the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics (ASPET). He has received numerous awards and honors, including the NARSAD Essel Investigator Distinguished Investigator Award, the ASPET-Astellas Awards in Translational Pharmacology, the Pharmacia - ASPET Award for Experimental Therapeutics, the Charles R. Park Award For Basic Research Revealing Insights into Physiology and Pathophysiology, the 2008 PhRMA Foundation Award for Excellence in Pharmacology and Toxicology, and was named as an ISI Most-Cited Scientists in Pharmacology & Toxicology. He serves on several national and international committees, including International Union of Pharmacology (IUPHAR) subcommittee on receptor nomenclature, the American Society for Pharmacology and Therepeutics (ASPET) Publications Board of Trust, ASPET Awards Committee, and is an Expert Consultant, Compound Selection Committee, Treatment Units for Research on Neurocognition and Schizophrenia (TURNS). Dr. Conn's current research is focused on development of novel treatment strategies for schizophrenia, Parkinson's disease, and other brain disorders.
Visit the Jeffrey Conn Research Group.